Compare BRC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRC | ERAS |
|---|---|---|
| Founded | 1914 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.0B |
| IPO Year | 2005 | 2021 |
| Metric | BRC | ERAS |
|---|---|---|
| Price | $98.07 | $18.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $1.20 | ★ $14.25 |
| AVG Volume (30 Days) | 158.6K | ★ 4.9M |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,144,698,000.00 | N/A |
| Revenue This Year | $7.36 | N/A |
| Revenue Next Year | $3.57 | N/A |
| P/E Ratio | $23.35 | ★ N/A |
| Revenue Growth | ★ 5.86 | N/A |
| 52 Week Low | $69.51 | $1.33 |
| 52 Week High | $99.29 | $24.28 |
| Indicator | BRC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 75.53 | 51.57 |
| Support Level | $78.82 | $17.63 |
| Resistance Level | $99.29 | $18.20 |
| Average True Range (ATR) | 2.02 | 1.27 |
| MACD | 0.32 | -0.28 |
| Stochastic Oscillator | 90.25 | 12.55 |
Brady Corp provides identification solutions and workplace safety products. The company offers identification and healthcare products that are sold under the Brady brand to maintenance, repair, and operations as well as original equipment manufacturing customers. Products include safety signs and labeling systems, material identification systems, wire identification, patient identification, and people identification. Brady also provides workplace safety and compliance products such as safety and compliance signs, asset tracking labels, and first-aid products. The company is organized and managed on a geographic basis with two reportable segments: Americas & Asia which derives maximum revenue, and Europe & Australia.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.